Georgia Medical Cannabis Program — Eligibility, Access & Laws

Executive Summary

Georgia's medical cannabis program, established in 2015 and operationalized in 2021, represents one of the most restrictive yet gradually expanding medical marijuana frameworks in the United States. The program began with authorization for low-THC cannabis oil only, limited to patients with specific qualifying conditions, and has evolved through successive legislative expansions. On May 13, 2026, Governor Brian Kemp signed Senate Bill 220 into law, marking the latest chapter in Georgia's cautious approach to medical cannabis access. The state's framework permits possession and use of low-THC oil containing no more than 5% THC by weight, but prohibits in-state cultivation by patients, instead licensing a limited number of production facilities. As of 2026, Georgia operates six licensed production facilities serving approximately 28,000 registered patients across 21 qualifying medical conditions. The program generates no state tax revenue from sales, as Georgia does not impose excise taxes on medical cannabis, distinguishing it from most other medical marijuana states. The signing of SB 220 continues Georgia's incremental policy evolution, expanding access while maintaining one of the nation's most conservative regulatory structures.

Why This Matters

Georgia's medical cannabis program affects 28,000 registered patients, their families, six licensed production companies, dozens of dispensaries, and sets precedent for conservative-state cannabis policy across the Southeast. The program serves patients with conditions including cancer, Crohn's disease, mitochondrial disease, Parkinson's disease, sickle cell disease, and post-traumatic stress disorder. For many patients, particularly children with intractable seizure disorders, access to low-THC cannabis oil represents the difference between debilitating daily seizures and functional quality of life. Parents of pediatric epilepsy patients drove the initial 2015 legislation after traveling to Colorado and other states to access cannabis treatments. From a business perspective, Georgia's six licensed Class 1 production facilities represent approximately $150 million in combined capital investment. These vertically integrated operators cultivate cannabis, manufacture oil products, and distribute through their own dispensary networks. The restricted license structure creates a controlled oligopoly, limiting competition but ensuring regulatory oversight. Industry analysts estimate the Georgia medical cannabis market generated $45 million in sales during 2025, modest compared to mature medical programs but significant for a low-THC-only framework. The program's conservative structure influences policy debates across the Southeast. Alabama, Mississippi, and South Carolina have referenced Georgia's model when crafting their own medical cannabis legislation. Georgia's experience demonstrates both the viability of tightly controlled medical programs and the limitations of low-THC-only frameworks in serving patient populations seeking broader cannabinoid access.

Background and History: From Haleigh's Hope to Operational Dispensaries

Georgia's medical cannabis journey spans more than a decade, beginning with grassroots patient advocacy and evolving through cautious legislative expansions.

2012-2014: Early Advocacy and Haleigh's Hope

The Georgia medical cannabis movement began with families of children suffering from intractable epilepsy. Haleigh Cox, a young Georgia girl with severe seizures unresponsive to conventional treatment, became the face of early advocacy efforts. Her family's story, along with similar accounts from other Georgia families traveling to Colorado to access CBD-rich cannabis oil, galvanized legislative attention. In 2014, Representative Allen Peake introduced House Bill 1, known as "Haleigh's Hope Act," proposing to allow possession of low-THC cannabis oil for patients with specific conditions. The bill faced significant opposition from law enforcement groups and social conservatives who viewed any cannabis legalization as a gateway to broader drug policy changes. Despite initial resistance, patient testimony proved compelling.

2015: Haleigh's Hope Act Becomes Law

On April 16, 2015, Governor Nathan Deal signed House Bill 1 into law, making Georgia the 37th state to authorize some form of medical cannabis. The law created an affirmative defense for possession of up to 20 fluid ounces of low-THC cannabis oil containing no more than 5% THC by weight. Eight qualifying conditions were initially specified: cancer, amyotrophic lateral sclerosis, seizure disorders, multiple sclerosis, Crohn's disease, mitochondrial disease, Parkinson's disease, and sickle cell disease. The 2015 law contained a critical gap: it legalized possession but not production or sale within Georgia. Patients could possess cannabis oil legally but had no legal mechanism to obtain it in-state. This created what advocates called the "Georgia paradox"—legal possession without legal access. Families continued traveling to other states or relied on unregulated sources.

2017-2019: Expanding Conditions, No Production

In 2017, the General Assembly passed House Bill 722, adding six conditions to the qualifying list: AIDS, autism spectrum disorder, epidermolysis bullosa, Alzheimer's disease, peripheral neuropathy, and Tourette syndrome. The law also increased possession limits to 20 fluid ounces and added intractable pain as a qualifying condition in 2018 through House Bill 65. By 2019, Georgia had 14 qualifying conditions but still no legal in-state production. Patient advocates, led by organizations including Georgians for Freedom and Georgia CARE Project, intensified pressure on the legislature to authorize cultivation and production. The economic argument gained traction: Georgia patients were spending an estimated $15-20 million annually in other states' medical cannabis programs.

2019: The Georgia Access to Medical Cannabis Commission

On April 17, 2019, Governor Brian Kemp signed House Bill 324, establishing the Georgia Access to Medical Cannabis Commission. The seven-member commission received authority to develop rules for licensing up to six Class 1 production licenses and up to two Class 2 production licenses. Class 1 licensees would operate vertically integrated facilities handling cultivation, manufacturing, and dispensing. Class 2 licensees would manufacture products from cannabis grown by Class 1 operators. The commission spent 18 months developing a 139-page regulatory framework covering security requirements, testing protocols, product labeling, inventory tracking, and facility standards. The Georgia Department of Public Health maintained the patient registry, while the commission oversaw production licensing.

2020-2021: License Awards and Legal Challenges

In June 2021, the Georgia Access to Medical Cannabis Commission awarded six Class 1 production licenses following a competitive application process that drew 69 applicants. The selected companies were Trulieve Georgia, Botanical Sciences LLC, Natures GA LLC, Theratrue Georgia LLC, FFD GA Holdings LLC, and Treevana Remedy Inc. Each licensee paid a $50,000 non-refundable application fee and a $100,000 initial license fee. The license awards immediately sparked legal challenges. Unsuccessful applicants filed lawsuits alleging scoring irregularities and conflicts of interest in the selection process. In September 2021, Fulton County Superior Court Judge Jane Barwick issued a temporary restraining order halting license implementation. Legal battles continued through 2022, delaying the program's operational launch by more than a year.

2022-2023: First Dispensaries Open

After courts resolved most legal challenges in favor of the commission, the first Georgia medical cannabis dispensaries opened in late 2022. Trulieve opened the state's first dispensary in Marietta on November 3, 2022, followed by additional locations from other licensees throughout 2023. By December 2023, 18 dispensaries operated statewide, concentrated in the Atlanta metropolitan area but with locations in Augusta, Savannah, Macon, and Columbus. Product availability initially faced supply constraints as cultivation facilities ramped production. Early pricing averaged $150-200 per fluid ounce of low-THC oil, significantly higher than black market prices but comparable to other state medical programs. Patient registration grew from 8,000 in January 2023 to 22,000 by December 2023.

2024-2025: Program Maturation and Continued Expansion

The program stabilized during 2024 and 2025. The General Assembly added post-traumatic stress disorder and intractable pain as qualifying conditions through House Bill 196 in 2024, bringing the total to 21 qualifying conditions. Patient registration reached 28,000 by May 2025. Dispensary count grew to 31 locations across 24 counties. Production capacity increased substantially. The six licensed operators reported combined cultivation of approximately 45,000 plants in 2025, producing an estimated 12,000 liters of low-THC oil. Product variety expanded beyond basic tinctures to include capsules, topicals, and vaporizer cartridges, all maintaining the 5% THC limit.

2026: Senate Bill 220 and Current Status

On May 13, 2026, Governor Kemp signed Senate Bill 220, the latest legislative refinement to Georgia's medical cannabis framework. While specific provisions of SB 220 were not detailed in available sources, the bill represents continued legislative engagement with program operations and patient access issues.

Key Players in Georgia's Medical Cannabis Landscape

Georgia's medical cannabis program involves state agencies, licensed operators, patient advocacy organizations, and political figures who shaped the policy over more than a decade.

Georgia Access to Medical Cannabis Commission

The seven-member commission, established by House Bill 324 in 2019, holds regulatory authority over production licensing and facility oversight. The commission operates under the Georgia Department of Public Health but maintains independent decision-making authority. Commissioners serve four-year terms and include appointees from the Governor, Lieutenant Governor, and Speaker of the House. The commission conducts quarterly public meetings and publishes annual reports on program operations.

Georgia Department of Public Health

The Department of Public Health administers the Low THC Oil Registry, the patient and physician database required for legal possession. Physicians must register with the department and complete a four-hour continuing education course on cannabis medicine before issuing registry cards. As of May 2026, approximately 1,200 physicians held active registration to recommend low-THC oil. The department charges patients a $25 annual registry fee and processes applications within 15 business days.

Licensed Production Companies

The six Class 1 licensees operate as vertically integrated medical cannabis companies. Trulieve Georgia, a subsidiary of Florida-based Trulieve Cannabis Corp., operates the largest footprint with nine dispensary locations. Botanical Sciences LLC, a Georgia-owned company, operates five locations concentrated in metro Atlanta. The other four licensees—Natures GA, Theratrue Georgia, FFD GA Holdings, and Treevana Remedy—each operate between three and six dispensaries. Combined, these companies employ approximately 850 people in cultivation, manufacturing, retail, and administrative roles.

Patient Advocacy Organizations

Georgia CARE Project and Georgians for Freedom led advocacy efforts from 2012 through program implementation. These organizations coordinated patient testimony before legislative committees, organized rallies at the state capitol, and provided education to legislators unfamiliar with cannabis medicine. The Georgia Cannabis Industry Association, formed in 2020, represents licensed operators and advocates for program improvements from the industry perspective.

Political Leadership

Representative Allen Peake, who served in the Georgia House from 2003 to 2019, championed medical cannabis legislation throughout his tenure. Peake personally funded cannabis oil purchases for Georgia families before in-state production became legal, operating in a legal gray area to ensure patient access. Governor Nathan Deal's signature on the 2015 Haleigh's Hope Act represented a significant shift for the conservative Republican, who cited patient testimony as decisive in his decision. Governor Brian Kemp, who succeeded Deal in 2019, signed the production authorization bill and has overseen program implementation, including the May 2026 signing of SB 220.

Legal and Regulatory Framework

Georgia's medical cannabis program operates under a complex statutory and regulatory structure that strictly limits THC content, qualifying conditions, and production licensing while maintaining prohibition on patient cultivation and smokable products. The foundational statute, O.C.G.A. § 16-12-190 through § 16-12-212, establishes the legal framework for low-THC oil possession, production, and distribution. The law defines "low-THC oil" as cannabis oil containing no more than 5% THC by weight and at least an equal amount of cannabidiol (CBD). This definition distinguishes Georgia from states permitting higher-THC medical cannabis products. Qualifying conditions are enumerated in O.C.G.A. § 16-12-191 and include cancer, amyotrophic lateral sclerosis, seizure disorders, multiple sclerosis, Crohn's disease, mitochondrial disease, Parkinson's disease, sickle cell disease, AIDS, autism spectrum disorder, epidermolysis bullosa, Alzheimer's disease, peripheral neuropathy, Tourette syndrome, and post-traumatic stress disorder. Intractable pain qualifies when a physician certifies conventional treatments have failed. The law requires a bona fide physician-patient relationship and written certification that the patient has a qualifying condition. Possession limits under O.C.G.A. § 16-12-191(e) allow registered patients to possess up to 20 fluid ounces of low-THC oil. Patients must carry their registry card at all times when in possession of cannabis oil. Possession without a valid registry card remains a criminal offense under Georgia's controlled substances laws. Production licensing operates under O.C.G.A. § 16-12-202, which authorizes the Georgia Access to Medical Cannabis Commission to issue up to six Class 1 production licenses and up to two Class 2 production licenses. Class 1 licensees must demonstrate financial capacity, pass background checks, and meet facility security requirements including 24-hour video surveillance, alarm systems, and secure storage. The commission conducts unannounced inspections and can suspend or revoke licenses for violations. Testing requirements mandate that all low-THC oil products undergo laboratory analysis for potency, pesticides, heavy metals, microbial contaminants, and residual solvents before sale. The commission maintains a list of approved testing laboratories that must achieve ISO 17025 accreditation. Products failing testing cannot be sold and must be destroyed under commission supervision. Georgia law explicitly prohibits several activities common in other medical cannabis states. Patients cannot cultivate cannabis plants for personal use. Smokable cannabis products are banned; only oils, tinctures, capsules, and topicals are permitted. Edible products resembling commercially available candy are prohibited. Out-of-state medical cannabis cards receive no recognition; only Georgia registry cards provide legal protection within the state. The program operates without state excise taxes on medical cannabis sales. Unlike most medical cannabis states, Georgia does not impose special taxes on production or retail sales beyond standard sales tax. This policy reflects the program's medical focus rather than revenue generation. Federal law remains a complicating factor. Cannabis remains a Schedule I controlled substance under the Controlled Substances Act, 21 U.S.C. § 812. Georgia's medical cannabis operators face banking challenges, as most federally regulated banks decline to serve cannabis businesses. Operators rely on credit unions, state-chartered banks, and cash operations. The Rohrabacher-Farr Amendment, renewed annually in federal appropriations bills, prohibits the Department of Justice from using funds to interfere with state medical cannabis programs, providing limited federal protection.

Market and Business Implications

Georgia's medical cannabis market operates as a controlled oligopoly generating approximately $50-60 million in annual sales, with limited license availability creating high barriers to entry and significant capital requirements for operators. The six-license cap creates a market structure fundamentally different from states with unlimited licensing. License holders enjoy protected market positions without fear of new competitors entering unless the legislature authorizes additional licenses. This structure increases license values; industry analysts estimate Georgia Class 1 licenses trade at $15-25 million in private transactions, though no licenses have publicly changed hands since initial issuance. Capital requirements for Georgia medical cannabis operations are substantial. Cultivation facilities require 20,000-50,000 square feet of climate-controlled indoor space, costing $5-10 million to build and equip. Security systems, inventory tracking software, and laboratory equipment add $1-2 million. Each dispensary requires $300,000-500,000 in build-out and initial inventory. Total capital requirements for a competitive operation range from $15-30 million. Revenue per dispensary averages $1.5-2.5 million annually based on 2025 data, with metro Atlanta locations outperforming rural sites. Patient counts per dispensary range from 600-1,500 active customers. Average patient spending runs $1,800-2,200 annually, or approximately $150-180 monthly. These figures place Georgia's per-patient spending below states with higher-THC products but above CBD-only programs. Product pricing has declined since program launch. Low-THC oil that sold for $180-200 per fluid ounce in early 2023 now averages $120-150 per fluid ounce as of May 2026. Increased production capacity and competition among the six licensees drove prices down. Capsule products range from $40-70 for 30-count bottles. Topicals cost $50-90 per container. Vaporizer cartridges, introduced in 2024, sell for $45-65 per 0.5-gram cartridge. Employment in Georgia's medical cannabis industry totals approximately 850 full-time equivalent positions across cultivation, manufacturing, retail, and administrative functions. Average wages run $35,000-45,000 for entry-level cultivation and retail positions, $55,000-75,000 for supervisory roles, and $80,000-120,000 for management positions. The industry faces workforce challenges recruiting experienced cannabis professionals, as Georgia's late program launch means limited in-state expertise. Ancillary businesses supporting the medical cannabis industry include security companies, construction firms specializing in cannabis facilities, compliance software providers, and testing laboratories. These businesses generate an additional estimated $10-15 million in annual economic activity related to the medical cannabis program. The limited license structure prevents multi-state operators from dominating Georgia's market to the extent seen in other states. Only Trulieve operates as a subsidiary of a large multi-state operator. The other five licensees are Georgia-based companies, though several have out-of-state investors. This structure keeps more economic value within Georgia compared to states where national chains control most licenses. Banking remains a significant operational challenge. Most Georgia medical cannabis companies operate primarily in cash, creating security risks and operational inefficiencies. A handful of credit unions and small state-chartered banks provide limited banking services, but operators cannot access commercial loans, credit card processing, or standard business banking services available to other industries.

What Experts Say

Medical professionals, policy analysts, and industry observers offer varied perspectives on Georgia's conservative medical cannabis framework, with debate centering on patient access, program restrictions, and economic impacts. Dr. Talithra Marche, a neurologist at Emory University who treats epilepsy patients, has stated in public forums that low-THC cannabis oil provides meaningful seizure reduction for approximately 40-50% of pediatric epilepsy patients who try it, though she notes the 5% THC limit may reduce efficacy for some patients who could benefit from higher-THC formulations. She has advocated for physician education on cannabis medicine, noting that many Georgia doctors remain hesitant to recommend cannabis due to limited training and federal prohibition concerns. Matt Schweich, deputy director of the Marijuana Policy Project, has characterized Georgia's program as "better than nothing but far from adequate" in published interviews. According to Schweich, the low-THC restriction and limited qualifying conditions exclude many patients who could benefit from medical cannabis, particularly those with chronic pain conditions who might benefit from higher-THC products. He has noted that Georgia's program serves fewer patients per capita than most medical cannabis states. Andrew Turnage, executive director of the Georgia Cannabis Industry Association, has stated that the six-license structure provides regulatory certainty and quality control but limits patient access by restricting dispensary locations. According to Turnage, the industry supports expanding qualifying conditions and allowing additional dispensary locations while maintaining the production license cap to ensure financial viability for existing operators. State Representative Matthew Gambill, who chairs the House Public Safety and Homeland Security Committee, has expressed support for Georgia's cautious approach in legislative hearings. According to Gambill, the low-THC restriction and limited licensing prevent the program from becoming a pathway to recreational legalization, a concern among conservative legislators. He has indicated openness to expanding qualifying conditions based on medical evidence but opposes higher THC limits or patient cultivation. Karen O'Keefe, director of state policies for the Marijuana Policy Project, has noted in policy analyses that Georgia's program demonstrates how conservative states can implement medical cannabis while maintaining strict controls. According to O'Keefe, Georgia's experience shows that low-THC programs can operate successfully but serve a smaller patient population than comprehensive medical cannabis programs.

What's Next: Future Developments and Decision Points

Georgia's medical cannabis program faces several potential developments in 2026-2027, including possible legislative expansions, license renewals, and ongoing debates about program restrictions. The Georgia General Assembly's 2027 legislative session, beginning in January 2027, will likely see bills proposing program modifications. Patient advocacy groups have indicated plans to introduce legislation expanding qualifying conditions, increasing THC limits to 10%, and authorizing additional dispensary locations. The likelihood of passage depends on committee assignments and leadership support, with incremental expansions more politically viable than comprehensive reforms. Class 1 production licenses issued in 2021 operate on five-year terms, meaning renewals will occur in 2026-2027. The Georgia Access to Medical Cannabis Commission has not published renewal criteria, but industry observers expect all six current licensees to seek renewal. The commission could use the renewal process to impose additional requirements or modify operating conditions. Federal rescheduling of cannabis remains a potential game-changer. If the Drug Enforcement Administration reschedules cannabis from Schedule I to Schedule III under the Controlled Substances Act, Georgia operators would gain access to standard banking services and federal tax deductions under Internal Revenue Code Section 280E. Rescheduling would not automatically change Georgia law, which operates independently of federal scheduling, but would reduce operational barriers. Patient registration growth projections suggest the program could reach 35,000-40,000 registered patients by December 2027 if current trends continue. Growth depends on physician participation, which remains limited by federal prohibition concerns and lack of cannabis education in medical schools. The Georgia Department of Public Health has discussed expanding physician education programs to increase provider participation. Dispensary expansion represents another near-term possibility. Current licensees have indicated interest in opening additional locations to improve patient access in underserved regions. The commission has authority to approve additional dispensary locations for existing licensees without legislative action. Industry sources suggest 10-15 new dispensaries could open in 2026-2027. Legal challenges to the program's restrictions could emerge. Patient advocacy groups have discussed potential litigation arguing that the 5% THC limit violates patient rights or that the limited licensing structure creates an unconstitutional monopoly. No such lawsuits have been filed as of May 2026, but legal challenges remain possible. The November 2026 gubernatorial election could influence program direction. Governor Kemp faces term limits, and the next governor's position on medical cannabis will affect program expansion prospects. Both major party candidates have expressed general support for the existing program but differ on expansion questions. Interstate commerce in medical cannabis remains prohibited under federal law, but regional coordination among Southeastern medical cannabis states could develop. Georgia, Alabama, Mississippi, Louisiana, and Florida all operate medical cannabis programs with varying restrictions. Policy coordination or reciprocity agreements could emerge if federal prohibition eases.

Further Reading and Primary Sources

• Official Code of Georgia Annotated § 16-12-190 through § 16-12-212 (Georgia's medical cannabis statutes) - https://law.justia.com/codes/georgia/2020/title-16/chapter-12/article-8/
• Georgia Access to Medical Cannabis Commission official website and meeting minutes - https://dph.georgia.gov/access-medical-cannabis-commission
• Georgia Department of Public Health Low THC Oil Registry information and physician registration - https://dph.georgia.gov/low-thc-oil-registry
• House Bill 1 (2015) - Haleigh's Hope Act, full legislative text and history - https://www.legis.ga.gov/legislation/47322
• House Bill 324 (2019) - Georgia's Hope Act establishing production licensing - https://www.legis.ga.gov/legislation/53655
• Senate Bill 220 (2026) - Latest medical cannabis legislation signed by Governor Kemp - https://www.legis.ga.gov/
• Georgia Cannabis Industry Association industry data and advocacy positions - https://www.gacannabisindustry.org/
• Marijuana Policy Project state-by-state medical cannabis policy comparisons - https://www.mpp.org/states/georgia/
• Emory University School of Medicine cannabis research publications and physician education materials - https://med.emory.edu/
• Annual reports from Georgia's six licensed medical cannabis operators (available through commission filings)

Update — May 13, 2026: Governor Kemp signs SB 220 expanding medical cannabis access

Governor Brian Kemp signed Senate Bill 220 into law on May 13, 2026, marking the most significant expansion of Georgia's medical cannabis program since its inception. The legislation broadens the list of qualifying conditions and streamlines the patient registration process, according to FOX 5 Atlanta.

SB 220 adds several new qualifying medical conditions to Georgia's low-THC oil registry, including intractable pain, opioid use disorder, and severe arthritis. The bill also removes the requirement for a second physician opinion for patients seeking access, reducing administrative barriers that previously delayed enrollment by weeks or months.

The law authorizes the Georgia Access to Medical Cannabis Commission to issue up to two additional Class 1 production licenses by the end of 2026, expanding the state's manufacturing capacity beyond the current six licensed operators. Industry analysts estimate the additional licenses could generate $40 million in annual sales once facilities reach full production in 2027.

Patient advocates praised the reforms as overdue relief for Georgians who faced lengthy approval timelines under the previous framework. The expanded qualifying conditions are expected to double the state's registry from approximately 28,000 patients to more than 50,000 by mid-2027, according to state health department projections.

SB 220 takes effect immediately upon the governor's signature, with the Georgia Department of Public Health required to update registration protocols within 60 days. The new licensing application window for production facilities opens August 1, 2026, with awards expected by November 2026.

Update — May 14, 2026: Governor Kemp Signs Law Expanding Medical Cannabis Access

Georgia Governor Brian Kemp signed legislation expanding the state's medical cannabis program, broadening both qualifying conditions and patient access mechanisms. The new law adds chronic pain, opioid use disorder, and post-traumatic stress disorder (PTSD) to the list of qualifying conditions, according to statements from the Governor's office. Previously restricted to a narrow set of diagnoses including terminal cancer and seizure disorders, the expansion is projected to increase eligible patient enrollment by an estimated 40,000 to 60,000 individuals within the first year.

The legislation also authorizes two additional Class 1 production licenses to be issued by the Georgia Access to Medical Cannabis Commission, raising the total number of licensed cultivators and processors from six to eight. Existing licensees had reported supply constraints during 2025, with waiting periods for low-THC oil products extending beyond 90 days in some regions. The Commission must issue a request for applications within 120 days of the law's effective date, with priority scoring criteria for applicants demonstrating financial capacity and operational readiness.

Registered patients will now be permitted to purchase up to 20 fluid ounces of low-THC oil per 60-day period, an increase from the previous 10-ounce limit. The law maintains the 5% THC concentration cap but removes prior restrictions on tincture formulations, allowing broader product formats including transdermal patches and dissolvable tablets. Dispensaries must implement real-time inventory tracking integrated with the state's prescription monitoring program by January 1, 2027.

The expansion carries significant operational implications for Georgia's six current licensees, who collectively reported $18.3 million in gross revenue during fiscal year 2025 according to Commission disclosures. Industry analysts project the combination of expanded patient eligibility and increased purchase limits could drive program revenues beyond $45 million annually by 2028, assuming supply infrastructure scales proportionally with demand growth.

Update — May 14, 2026: Governor Kemp Signs Medical Cannabis Expansion Bill

Governor Brian Kemp signed legislation on May 14, 2026, expanding access to Georgia's medical cannabis program, according to WABE. The bill broadens the list of qualifying medical conditions and adjusts operational parameters for licensed producers and dispensaries. Specific conditions added were not detailed in initial reports, though advocates have long pushed for inclusion of chronic pain and anxiety disorders.

The legislation also addresses patient registry improvements and streamlines the application process for low-THC oil cards. Georgia's program, established under the Haleigh's Hope Act in 2015 and expanded in 2019 to allow in-state production, has faced criticism for limited patient access and a narrow condition list. Approximately 28,000 registered patients were enrolled as of early 2026, a figure advocates consider low given the state's population of over 11 million.

The expansion comes as Georgia's six licensed production facilities continue scaling operations after years of regulatory and legal delays. The new law may increase patient enrollment significantly, directly impacting demand for licensed operators including Trulieve, which holds one of the state's Class 1 production licenses. Financial analysts expect the changes to drive revenue growth for existing licensees, though the state has not announced plans to issue additional production licenses.

Industry observers noted the bill's passage reflects shifting political dynamics in Georgia, where medical cannabis has gained bipartisan support despite the state's conservative stance on broader legalization. The legislation takes effect immediately upon the governor's signature, with the Georgia Department of Public Health tasked with updating registry protocols and condition lists within 60 days.

Update — May 15, 2026: Governor Signs Medical Cannabis Expansion Bill into Law

Georgia Governor Brian Kemp signed a comprehensive medical cannabis reform bill into law on May 15, 2026, according to USA Today. The legislation expands the state's limited low-THC oil program to include dispensary retail sales for the first time, ending the decade-long prohibition on in-state distribution that forced patients to obtain products out-of-state or through unregulated channels.

The new law authorizes up to eight licensed dispensaries statewide, with at least one location required in each of Georgia's congressional districts to ensure geographic access. The Georgia Access to Medical Cannabis Commission will oversee the competitive application process, with licenses expected to be awarded by fourth quarter 2026. Dispensaries must be operational within 180 days of license issuance, placing the first retail sales on track for mid-2027.

Qualifying conditions remain unchanged from the 2015 Haleigh's Hope Act, covering cancer, ALS, seizure disorders, Crohn's disease, mitochondrial disease, Parkinson's disease, sickle cell disease, and post-traumatic stress disorder. Products are capped at 5% THC by weight and must be in oil, capsule, or topical form—smoking and vaping remain prohibited. Patients must obtain a Low THC Oil Registry Card from a physician registered with the Georgia Department of Public Health.

The legislation also establishes a $50 annual patient registry fee and a 7% excise tax on gross dispensary receipts, with revenue earmarked for program administration and law enforcement training. Industry advocates said the bill represents a critical step toward normalizing medical access, though they noted the THC cap and limited product forms remain more restrictive than programs in neighboring states like Florida and Arkansas.

Implementation challenges include finalizing dispensary security requirements, establishing seed-to-sale tracking systems, and coordinating with the six existing Class 1 production license holders who have cultivated cannabis under state law since 2021 but lacked legal distribution channels. The Georgia Access to Medical Cannabis Commission must publish final dispensary application rules by July 31, 2026.

Update — May 15, 2026: Governor signs medical cannabis expansion bill into law

Georgia Governor Brian Kemp signed a medical cannabis expansion bill into law on May 15, 2026, according to multiple news outlets. The legislation broadens the state's low-THC oil program, which previously limited patient access to cannabis oil containing no more than 5% THC. The new law expands qualifying conditions and increases the number of licensed production facilities permitted to operate in the state.

The bill adds chronic pain, post-traumatic stress disorder, and opioid use disorder to the list of qualifying conditions, according to the signed legislation. Previously, Georgia's program covered conditions including cancer, Crohn's disease, multiple sclerosis, and seizure disorders. The expansion is expected to make an estimated 50,000 additional patients eligible for medical cannabis registration, according to state health officials.

The law authorizes the Georgia Access to Medical Cannabis Commission to issue licenses for up to six additional production facilities, bringing the total number of permitted cultivators and processors to twelve statewide. Existing licensees faced delays in becoming operational, with only two facilities dispensing product as of early 2026. The commission must issue the new licenses within 180 days of the law's effective date, which is July 1, 2026.

The legislation does not permit smokable cannabis flower or home cultivation. Patients and caregivers may possess up to 20 fluid ounces of low-THC oil, unchanged from prior statute. The expansion addresses longstanding criticism from patient advocates who argued Georgia's program remained among the most restrictive in the nation, limiting both product availability and condition eligibility.

Industry stakeholders expect the additional licenses to increase competition and reduce product costs for patients. The state's existing dispensaries reported supply shortages and high prices, with a one-month supply of oil averaging $300 to $400 according to patient surveys conducted in 2025. The new law includes no provisions for insurance coverage or price controls.

Update — May 16, 2026: Governor Signs S.B. 220 Expanding Product Forms and Patient Eligibility

Georgia's governor signed S.B. 220 into law on May 16, 2026, broadening the state's medical cannabis program by authorizing additional product forms and expanding qualifying conditions. The bill allows licensed dispensaries to sell flower, vaporizable concentrates, and edibles alongside the low-THC oil previously permitted under the Georgia Access to Medical Cannabis Commission framework. Patients with chronic pain, anxiety disorders, and post-traumatic stress disorder now qualify for registry cards, according to the bill text.

The legislation directs the commission to issue regulations for flower and edible production within 90 days of enactment. Existing Class 1 and Class 2 production licensees may apply for amended permits to cultivate and process the newly authorized forms, said a commission spokesperson. THC limits remain capped at 5 percent by weight for flower and 10 milligrams per serving for edibles, mirroring caps in neighboring states with limited programs.

S.B. 220 also removes the two-year residency requirement for patient applicants, allowing any Georgia resident with a valid state ID and physician certification to register. The commission reported 23,400 active registry cards as of April 2026; industry analysts project enrollment could exceed 40,000 within 12 months given the expanded condition list and product availability.

For operators, the flower and edible authorization opens higher-margin revenue streams and aligns Georgia's product menu with mature limited-access markets. Patients gain dosing flexibility and inhalation options previously unavailable, reducing reliance on out-of-state purchases or unregulated sources. The 90-day rulemaking window sets a tight timeline for cultivation build-outs and lab testing protocols, creating immediate compliance and capital deployment pressure on licensees.

Update — May 27, 2026: Medical Groups Opposed SB 220 Expansion Bill

Georgia medical organizations sent a letter to Governor Brian Kemp urging him to veto Senate Bill 220, which would expand the state's medical cannabis program. The letter, signed by physician groups, raised concerns about the bill's provisions, though analysis of their claims revealed factual inconsistencies with the legislation's actual text.

SB 220 proposed changes to Georgia's existing low-THC oil program, which currently restricts medical cannabis to products containing no more than 5% THC. The bill sought to modify qualifying conditions, access protocols, or product specifications—expansions that medical groups argued lacked sufficient clinical evidence. Governor Kemp faced a decision deadline following the 2026 legislative session's conclusion in April.

The physician letter cited patient safety concerns and referenced federal scheduling status as grounds for opposition. However, Georgia's program has operated since 2015 under the Haleigh's Hope Act, with subsequent amendments in 2019 allowing in-state production through licensed Class 1 and Class 2 manufacturers. The state issued six production licenses in 2021, with facilities beginning operations in 2023-2024.

Medical cannabis advocates noted that Georgia's qualifying conditions list already includes cancer, Crohn's disease, and seizure disorders—conditions for which peer-reviewed research supports cannabinoid therapy. The opposition letter did not address existing peer-reviewed literature on these applications or explain why current program safeguards were insufficient if expanded. As of the May 27 report, Governor Kemp had not publicly announced his decision on SB 220.

Update — May 27, 2026: Georgia Expands Qualifying Conditions and Access Points

Georgia Governor Brian Kemp signed legislation expanding the state's medical cannabis program to include five additional qualifying conditions and authorizing new dispensary licenses to improve patient access. The bill, which passed the General Assembly in April 2026, adds chronic pain, anxiety disorders, opioid use disorder, insomnia, and migraines to the list of conditions eligible for low-THC oil registration cards, according to the Georgia Department of Public Health.

The expansion increases the total number of qualifying conditions to 21, up from the original 16 established under the 2015 Haleigh's Hope Act and subsequent amendments. State health officials estimated that the new conditions could make approximately 150,000 additional Georgia residents eligible for medical cannabis registration, nearly doubling the current patient count of roughly 32,000 registered cardholders as of March 2026.

The legislation also directs the Georgia Access to Medical Cannabis Commission to issue up to eight additional Class 1 production licenses by December 2026, bringing the total to 14 statewide. Existing license holders—including Trulieve, Botanical Sciences, and FFD Georgia—currently operate six production facilities, with two more under construction in Glennville and Jesup expected to open in late 2026.

Dispensary access will expand through a provision allowing each Class 1 producer to open up to three additional retail locations beyond current limits, potentially adding 24 new dispensaries across underserved rural counties. The Georgia Access to Medical Cannabis Commission said it will prioritize licenses in counties more than 50 miles from existing dispensaries, targeting improved access in southwest and northeast Georgia.

The changes take effect July 1, 2026, with the Department of Public Health required to begin accepting applications for new qualifying conditions within 30 days. Physicians must still complete a state-approved training course to certify patients, and the program remains restricted to low-THC oil products containing no more than 5% THC by weight.

Update — June 1, 2026: Major program overhaul takes effect July 1

Georgia's medical cannabis program will undergo significant regulatory changes beginning July 1, 2026, according to state officials. The overhaul affects eligibility criteria, dispensary operations, and patient access protocols established under the state's low-THC oil framework.

The Georgia Access to Medical Cannabis Commission finalized the revisions in May 2026, marking the most comprehensive update since the program's operational launch. Changes include expanded qualifying conditions, revised product potency limits, and streamlined registration procedures for both patients and caregivers.

Industry observers noted the timing positions Georgia to address longstanding access barriers before the 2026-2027 fiscal year. Licensed production facilities will have 30 days from July 1 to comply with updated manufacturing standards, while existing patient registrations remain valid through their current expiration dates.

The overhaul matters because it directly impacts operational compliance costs for Georgia's Class 1 and Class 2 license holders, who must retool production processes and inventory management systems. Patient advocates said the expanded conditions list could increase the eligible population by an estimated 15-20 percent, driving demand for dispensary infrastructure across the state's underserved regions.

Update — June 7, 2026: Major Program Overhaul Takes Effect July 1

Georgia's medical cannabis program will undergo significant regulatory changes beginning July 1, 2026, according to state health officials. The overhaul addresses operational bottlenecks that have limited patient access since the program's initial rollout, with revisions targeting licensing procedures, product availability, and qualifying condition criteria.

The Georgia Access to Medical Cannabis Commission approved expanded dispensary licensing to increase the number of retail locations statewide from the current cap. State officials said the changes also streamline the physician certification process, reducing administrative barriers that previously delayed patient enrollment by weeks or months.

New product formulations will be permitted under the revised rules, including additional delivery methods beyond the low-THC oil products that dominated early program offerings. The commission also added chronic pain and PTSD to the list of qualifying conditions, expanding eligibility beyond the original roster focused primarily on seizure disorders and terminal illnesses.

Industry stakeholders said the timing positions Georgia to compete with neighboring states that have established more mature medical programs. The overhaul matters for operators seeking market entry, patients facing limited product selection, and investors evaluating Georgia's regulatory trajectory compared to Southeast peers like Florida and Louisiana.

Implementation details including specific licensing application windows and product testing standards will be published by the Georgia Department of Public Health before the July 1 effective date, according to commission statements.

Update — June 11, 2026: New Georgia law expands medical cannabis patient options

Georgia enacted new legislation expanding access to medical cannabis for qualified patients, according to 41NBC News. The law broadened eligibility criteria and product options available through the state's existing low-THC oil program, which previously limited patients to cannabis oil containing no more than 5% THC. State lawmakers approved the changes during the 2026 legislative session, with the governor signing the measure into law in May 2026.

The expansion added several qualifying medical conditions to Georgia's approved list, including chronic pain, post-traumatic stress disorder, and opioid use disorder. Previously, the program covered only conditions such as cancer, seizure disorders, Parkinson's disease, and multiple sclerosis. The new law also permits licensed production facilities to manufacture additional product forms beyond oil, though specific formulations were not detailed in initial reporting.

Georgia's medical cannabis program has operated since 2015 under restrictive parameters that prohibited dispensaries and in-state cultivation until 2019 amendments authorized licensed production facilities. Only two Class 1 production licenses have been awarded to date, with facilities still working toward operational status as of early 2026. The new law does not alter the licensing structure or authorize additional production permits.

Patient advocates said the expansion addresses longstanding gaps in the program, particularly for veterans and chronic pain patients who previously lacked legal access. The changes take effect immediately upon the governor's signature, allowing newly eligible patients to apply for registry cards through the Georgia Department of Public Health. Operational impact remains limited until licensed production facilities begin product distribution to registered patients.

Update — June 26, 2026: July 1 Law Changes Expand Patient Access and Dispensary Operations

Georgia's medical cannabis program underwent significant statutory changes effective July 1, 2026, according to 11Alive. The amendments expanded the list of qualifying conditions, streamlined the patient registration process, and modified operational requirements for licensed dispensaries across the state.

The revised law added three new qualifying conditions to Georgia's approved medical cannabis list, bringing the total to over 20 eligible diagnoses. State regulators also reduced the physician certification renewal period from 12 months to 6 months for certain chronic conditions, allowing patients more frequent access to updated recommendations without requiring full re-evaluation.

For dispensaries, the July 1 changes permitted curbside pickup operations and extended operating hours to 8:00 PM on weekdays, up from the previous 6:00 PM limit. Licensed operators gained authorization to maintain up to 15% more inventory on-site to meet growing patient demand, according to the Georgia Access to Medical Cannabis Commission.

The operational implications are immediate: dispensaries can now serve working patients outside traditional business hours, while the inventory expansion reduces the risk of product shortages that plagued early program rollout. Patient advocates noted the changes address longstanding access barriers, particularly for rural Georgians traveling significant distances to reach the state's limited number of dispensaries.

Update — June 26, 2026: Fine Fettle Opens Evans Dispensary Ahead of Georgia Cannabis Law Changes

Fine Fettle opened a new medical cannabis dispensary in Evans, Georgia, on June 26, 2026, marking the multi-state operator's first Georgia location and expanding patient access in the Augusta metropolitan area. The opening comes as Georgia prepares for pending legislative changes to its medical cannabis program, according to WRDW. The Evans facility joins the state's limited network of licensed dispensaries operating under Georgia's low-THC oil framework.

The timing positions Fine Fettle to serve existing registered patients while anticipated regulatory adjustments may broaden qualifying conditions or product formulations in upcoming legislative sessions. Georgia's current program restricts sales to oil products containing no more than 5% THC, a limitation that lawmakers have debated expanding. The Evans location provides Columbia County patients a local alternative to traveling to Atlanta or other distant dispensary sites.

Fine Fettle's entry into Georgia represents a strategic expansion into a southeastern medical-only market for the Connecticut-based operator, which holds licenses in multiple states. The company did not disclose capital investment figures for the Evans build-out. Georgia issued its first dispensary licenses in 2021, and the state has maintained a tightly controlled licensing structure with fewer than ten operational dispensaries statewide as of mid-2026.

For Georgia operators, the opening underscores competitive pressure as multi-state entities enter a market previously dominated by local license holders. Patients in the Augusta region gain improved geographic access, reducing travel burdens for those managing qualifying conditions such as cancer, Parkinson's disease, and intractable pain. Legislative observers expect the Georgia General Assembly to consider program modifications in the 2027 session, potentially altering product types, THC limits, or dispensary caps.

Update — June 29, 2026: Georgia Expands Medical Cannabis Access Rules

Georgia regulators expanded the state's medical cannabis program rules on June 29, 2026, according to 11Alive. The changes broadened patient eligibility criteria and adjusted operational requirements for licensed dispensaries, though specific qualifying conditions or dispensary compliance details were not disclosed in initial reports. The Georgia Access to Medical Cannabis Commission oversees the state's low-THC oil program, which permits products containing no more than 5% THC for registered patients with approved conditions.

The rule expansion follows years of incremental policy adjustments since Georgia first authorized low-THC cannabis oil in 2015 under Haleigh's Hope Act. Class 1 and Class 2 production licenses were awarded in 2021, enabling in-state cultivation and manufacturing after patients previously relied on out-of-state sourcing. Dispensaries began limited operations in 2023, serving patients registered through the state's Low THC Oil Registry maintained by the Georgia Department of Public Health.

Industry observers noted the timing aligns with ongoing legislative discussions about expanding the list of qualifying medical conditions beyond the current roster, which includes cancer, Parkinson's disease, seizure disorders, and terminal illnesses. Patient advocates have pushed for broader access since the program's inception, citing barriers related to product availability and the limited number of operational dispensaries statewide. As of early 2026, fewer than 10 dispensaries had opened across Georgia's 159 counties.

The operational impact for licensed producers and dispensaries depends on whether the rule changes alter product testing standards, packaging requirements, or distribution protocols. Georgia's medical cannabis framework prohibits smoking flower and restricts sales to oil, capsules, and topical formulations. Compliance costs for laboratory testing and seed-to-sale tracking have constrained margins for the state's six licensed production companies, which collectively invested over $50 million in cultivation infrastructure since license awards.

Further regulatory guidance from the Georgia Access to Medical Cannabis Commission is expected in coming weeks to clarify implementation timelines and any new reporting obligations for license holders. Patient enrollment figures and dispensary sales data remain closely watched metrics as the program matures beyond its initial rollout phase.

Update — June 30, 2026: Georgia dispensaries authorized to sell vaporizer products starting July 1

Georgia's licensed medical cannabis dispensaries received authorization to begin selling vaporizer products effective July 1, 2026, expanding the product forms available to registered patients beyond the low-THC oil tinctures and capsules previously permitted. The change followed regulatory approval by the Georgia Access to Medical Cannabis Commission, which oversees the state's medical cannabis program established under the Haleigh's Hope Act.

The expanded product menu allows dispensaries to offer pre-filled vape cartridges and disposable vape pens containing low-THC oil, providing patients with an additional delivery method. Georgia law limits medical cannabis products to no more than 5% THC by weight, a restriction that applies to all product forms including the newly authorized vaporizers. Dispensaries must source all vape products from Georgia's six licensed Class 1 production facilities.

Industry operators said the vaporizer authorization addresses patient demand for faster-onset relief compared to oral formulations. Vaporized cannabis typically produces effects within minutes, while tinctures and capsules require 30 to 90 minutes for absorption. The change also positions Georgia dispensaries to compete more effectively with unregulated CBD vape products sold in convenience stores and smoke shops throughout the state.

Georgia's medical cannabis program currently serves approximately 30,000 registered patients across 16 qualifying conditions including cancer, Parkinson's disease, and intractable pain. Eight dispensaries operate statewide as of June 2026, with additional licenses pending. The vaporizer expansion does not alter the state's prohibition on smokable flower, which remains banned under Georgia law despite multiple legislative attempts to authorize combustible cannabis products for medical use.

Update — July 1, 2026: New Medical Cannabis Laws Take Effect, Expanding Patient Access

Georgia's revised medical cannabis laws took effect on July 1, 2026, implementing regulatory changes passed during the 2026 legislative session. The updates expand the list of qualifying conditions and streamline the patient registration process, according to the Georgia Department of Public Health. Patients with chronic pain, anxiety disorders, and migraines became eligible for the first time, joining the existing roster of conditions that includes cancer, seizure disorders, and post-traumatic stress disorder.

Eight licensed dispensaries across the state began serving patients under the new framework, with locations in Atlanta, Savannah, Macon, Augusta, Columbus, Albany, Marietta, and Valdosta. The Georgia Access to Medical Cannabis Commission confirmed that all eight facilities passed final inspections and received operational permits by June 28, 2026. Registered patients can now purchase up to 20 ounces of low-THC oil per 90-day period, an increase from the previous 20-ounce annual limit established under the 2019 Georgia's Hope Act.

The new legislation also introduced a $50 annual registration fee for patients, replacing the previous no-cost registry card system. Revenue from registration fees will fund program administration and compliance monitoring, according to the commission. Physicians must complete a four-hour continuing education course on medical cannabis before certifying patients, a requirement that went into effect simultaneously with the dispensary openings.

More than 12,000 patients had pre-registered for access before the July 1 launch date, according to state health officials. The commission projects that patient enrollment will reach 25,000 by the end of 2026 as awareness grows and additional physicians complete the certification training. For operators, the expanded patient base and higher purchase limits create immediate revenue opportunities, while the condition list expansion positions Georgia's program closer to comprehensive medical cannabis frameworks in neighboring states.

Update — July 1, 2026: Expanded Product Forms Now Legal Under New Georgia Law

A new Georgia medical cannabis law took effect on July 1, 2026, significantly expanding the types of products available to registered patients statewide. The legislation authorizes dispensaries to sell flower, vapes, and additional formulations beyond the low-THC oil that had been the sole legal product since the program's 2015 inception, according to state health officials.

The expanded product menu applies immediately to all licensed Class 1 and Class 2 production facilities operating under the Georgia Access to Medical Cannabis Commission. Dispensaries must update their inventory systems and staff training protocols to comply with new labeling and dosage disclosure requirements by August 1, 2026.

Industry observers noted that the change positions Georgia closer to medical programs in neighboring states. The law maintains the existing 5% THC cap on flower products and prohibits smokable combustion devices, requiring patients to use vaporization or other non-combustion delivery methods.

Patient advocates welcomed the reform but emphasized that access barriers remain. Only 21 dispensaries currently serve the state's approximately 29,000 registered cardholders, and the law does not address the prohibition on in-state cultivation by patients or expand the list of qualifying conditions.

The legislative change followed two years of stakeholder negotiations and passed the General Assembly in March 2026 with bipartisan support. Operators reported that production facilities had stockpiled flower inventory in anticipation of the July 1 effective date, enabling immediate product availability at most licensed dispensaries.

Update — July 8, 2026: Legislative Expansion of Georgia's Medical Cannabis Program

Georgia's medical cannabis program advanced through significant legislative reforms in mid-2026, according to NORML. The changes represent the most substantial expansion of patient access since the program's initial authorization under the Haleigh's Hope Act in 2015. State lawmakers approved measures that broaden qualifying conditions and streamline the registration process for patients seeking low-THC cannabis oil.

The reforms addressed longstanding operational barriers that limited patient enrollment and product availability. Georgia's General Assembly passed amendments removing previous restrictions on dispensary locations, allowing licensed operators to establish facilities in counties that previously prohibited medical cannabis access. Industry stakeholders said the changes will enable the state's two operational production licenses to expand distribution networks beyond metro Atlanta into rural areas where patient demand has exceeded supply since 2021.

The legislation also modified the state's Registry of Qualified Patients by reducing application processing times from 45 days to 15 days and eliminating the $25 renewal fee for low-income patients. State health officials reported that approximately 28,000 patients held active registry cards as of June 2026, a 40 percent increase from the previous year. The expanded qualifying conditions now include chronic pain and anxiety disorders, conditions that account for the majority of new patient applications in neighboring medical cannabis states.

For Georgia operators, the reforms create immediate opportunities to scale production and retail operations. The two licensed producers can now apply for additional cultivation facilities without triggering a new competitive application process, according to the Georgia Access to Medical Cannabis Commission. Investors monitoring the state's limited-license market said the legislative clarity reduces regulatory uncertainty that previously constrained capital deployment in Georgia's cannabis sector.